Table 2.
HLA and MAGE-A10 expression, ADP-A2M10 dose, and response in individual patients (mITT) with various tumor types at screening.
| Patient ID | Age (years) Sex | Tumor Type | Prior Therapy a | HLA-A Allele 1/Allele 2 | MAGE-A10 P-score b (% <1+, 1+, 2+, 3+) | MAGE-A10 H-score c | Actual ADP-A2M10 dose (cells ×109) | Response/(Max %Change in SLD) DoSD d |
|---|---|---|---|---|---|---|---|---|
| 1 | 66 M | HNSCC | 1, 2, 3, 4 | 01:01 02.01 | 0, 10, 30, 60 | 250 | 0.1 | PD |
| 2 | 61 M | HNSCC | 1, 2, 4 | 02:01 3:01 | 30, 20, 40, 10 | 130 | 0.1 | NE |
| 3 | 47 M | Mel | 1, 2, 4 | 02:01 25:01 | 0, 40, 30, 30 | 190 | 0.09 | PD |
| 4 | 58 M | UC | 1, 2, 4 | 02:01 26:01 | 35, 40, 20, 5 | 95 | 5.26 | SD (3.8%) 65 days |
| 5 | 46 F | HNSCC | 1, 2, 4 | 02:0124:AUJRX | 5, 5, 70, 20 | 205 | 5.99 | PD |
| 6 | 66 M | UC | 1, 3 | 02:01 26:01 | 20, 30, 30, 20 | 150 | 5.51 | SD (12.3%) 246 days |
| 7 | 76 M | HNSCC | 1, 2, 4 | 02:01 11:01 | 0, 0, 20, 80 | 280 | 3.97 | PD |
| 8 | 47 F | Mel | 1, 2 | 01:01 02:01 | 60, 5, 5, 30 | 105 | 4.87 | PD |
| 9 | 65 M | Mel | 2, 4 | 01:01 02:01 | 10, 20, 50, 20 | 180 | 6.53 | SD (1.1%) 122 days |
| 10 | 68 M | UC | 1, 2, 4 | 02:01 25:01 | 0, 5, 5, 90 | 285 | 13.63 | SD (0%) 36 days |
1, Chemotherapy; 2, Immunotherapy; 3, Targeted therapy; 4, Radiotherapy.
P-score is immunohistochemical positivity determined by a pathologist based on both percentage of positive tumor cells and intensity of expression.
H-score is derived by 1 × (% of 1+ cells) + 2 × (% of 2+ cells) + 3 × (% of 3+ cells).
DoSD only analyzed in patients with SD.
DoSD, duration of stable disease; F, female; HLA, human leukocyte antigen; HNSCC, head and neck squamous cell carcinoma; M, male; MAGE, melanoma-associated antigen; Mel, melanoma; mITT, modified intent-to-treat; NE, not evaluable; PD, progressive disease; SD, stable disease; SLD, sum of the longest diameters of the target lesions; UC, urothelial carcinoma.